CRISPR Therapeutics AG (CRSP)

Market Cap	5.23B -18.1%
Revenue (ttm)	13.39M -64.8%
Net Income	-451.14M
EPS	-4.76
Shares Out	96.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	994,892
Open	50.82
Previous Close	50.44
Day's Range	50.52 - 54.05
52-Week Range	44.12 - 78.38
Beta	1.76
Analysts	Buy
Price Target	87.50 (+61.83%)
Est. Earnings	Nov 9, 2026

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as deve...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 19, 2016
• Employees: 393
• Stock Exchange: Nasdaq
• Ticker Symbol: CRSP
• Website: https://www.crisprtx.com

Financial Performance

In 2025, CRISPR Therapeutics AG's revenue was $3.51 million, a decrease of -90.59% compared to the previous year's $37.31 million. Losses were -$581.60 million, 58.8% more than in 2024.

Analyst Summary

According to 22 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price target is $87.5, which is an increase of 61.83% from the latest price.

Price Target

$87.5

(61.83% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 9, 2026

Data Sources Report a data error